Please find enclosed Secretarial Compliance Report duly issued by R&D Company Secretaries, Practicing Company Secretaries for the financial year ended March 31, 2026.
PANACEABIO · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Panacea Biotec Ltd has filed its annual Secretarial Compliance Report for the financial year ended March 31, 2026, as mandated under SEBI LODR Regulations. The report, issued by R&D Company Secretaries (Practicing Company Secretaries), confirms that the company has complied with all applicable statutory provisions including SEBI regulations on listing requirements, insider trading, and related party transactions. One prior-year issue was addressed: the company had failed to provide prior intimation for a Board Meeting on dividend for FY 2023-24, for which it paid a fine of Rs. 11,800 (including GST) to each of NSE and BSE. The company has since taken corrective measures to ensure timely intimation to stock exchanges going forward. All 13 compliance checkpoints including secretarial standards, website disclosures, director disqualification, and subsidiary reporting showed 'Yes' (compliant) status.
This is a routine compliance filing with no material concerns for shareholders. The company has demonstrated adherence to SEBI regulatory requirements for FY 2025-26, and the prior-year compliance issue has been resolved with penalty paid.